AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

Feb 8, 2024 - 18:00

AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

Read the original article

Tags:

Previous Article

INCB-57643 by Incyte for Myelofibrosis: Likelihood of Approval

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) by Citius Pharmac...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Kid EDV by ImmunityBio for Pediatric Diffuse Intrinsic ...

Jun 5, 2023

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-...

Sep 18, 2024

EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC

EMA CHMP supports CStone’s sugemalimab for metastatic N...

Jun 4, 2024